Table 3.

Abnormality in FISH, defined as 2 or more markers abnormal among the four tested markers, by time between sputum collection and the date of lung cancer incidence, by cancer histology, and by cancer stage

CharacteristicCasesOR (95% CI)*
n/N abnormal%Age-adjusted modelFully adjusted model
Time between sputum collection and lung cancer incidence
    More than 18 mo14/45312.0 (0.7-5.6)1.7 (0.6-5.3)
    Within 18 mo42/557624.1 (8.8-65.8)29.9 (9.5-94.1)
Among samples collected within 18 mo before diagnosis
    Lung cancer histology
        Squamous cell15/1694131.1 (13.6-999)Not estimable
        Adenocarcinoma11/176512.9 (3.6-46.2)16.4 (3.7-72.2)
        Small cell3/56010.2 (1.4-73.7)4.7 (0.2-99.9)
        Others10/137729.8 (6.0-148.8)77.8 (7.9-764.5)
        Unknown3/47521.0 (1.7-254.4)10.3 (0.4-242.4)
    Lung cancer stage
        Localized (stage I)14/1593123.5 (12.4-999)Not estimable
        Regional (stage II, IIIA)4/75712.2 (2.0-73.5)15.7 (2.1,118.6)
        Distant (stage IIIB, IV)8/14579.0 (2.4-34.7)20.6 (3.6-118.0)
        Unknown16/198439.8 (9.1-173.4)37.7 (7.6-186.8)
  • *ORs comparing cases to the pooled control group, among whom there were 7 of 59 (12%) who had ≥2 abnormal FISH markers for ≤18 mo proximal samples and 7 of 37 (19%) who had ≥2 abnormal FISH markers for >18 mo proximal samples.

  • Adjusted for age, sex, FEV1, pack-years of smoking, and current smoking status.